Arbutus to discontinue ab-452 and pursue development of next generation oral hbv rna-destabilizer

Arbutus announces decision to discontinue ab-452 and to pursue development of a next generation hbv specific oral rna-destabilizer.arbutus biopharma corp - arbutus expects to announce ab-729 preliminary phase 1a/1b data late q12020.arbutus biopharma corp - continue research and development of a next generation oral hbv rna-destabilizer.arbutus biopharma corp - reiterated its earlier guidance for both ab-729 and ab-836.arbutus biopharma - for ab-836, arbutus' next generation capsid inhibitor, expects to complete investigational new drug enabling studies by year end.arbutus biopharma corp - look forward to announcing our preliminary safety and efficacy data for ab-729 later this quarter.
ABUS Ratings Summary
ABUS Quant Ranking